Clostridioides difficile infections (CDIs) observed an unexpected resolution of COVID-19 symptoms. It is not clear whether or not the FMTs were responsible, and two such cases are not enough to draw hard conclusions.
However, the apparent response of COVID-19 to the FMTs suggests that further investigation may be necessary.Both people with CDIs appeared to be in the beginning stages of SARS-CoV-2 infections, with early COVID-19 symptoms that resolved shortly after their FMTs.“Our main conclusion from these cases,” say the study authors, “is that FMT appears safe and of comparable efficacy in treating recurrent CDI in patients with coexisting COVID-19.